Suven Life jumps on product patents

Suven Life Sciences announced today morning that it has been granted two product patents from Canada and one product patent from China. These are for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of  20 granted patents from Canada and 18 granted patents from China. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

The market is obviously happy with this development as the stock is up over 4% at Rs.241.55 with an intra day high and low of Rs.245 and Rs.233.30 respectively.